# A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

> **NCT00328549** · PHASE2 · COMPLETED · sponsor: **Ortho Biotech Products, L.P.** · enrollment: 105 (actual)

## Conditions studied

- Hepatitis C
- Anemia

## Interventions

- **DRUG:** Pegylated Interferon and Ribavirin

## Key facts

- **NCT ID:** NCT00328549
- **Lead sponsor:** Ortho Biotech Products, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2002-12
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328549, "A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00328549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*